Kekitiinwa Addy, Lee Katherine J, Walker A Sarah, Maganda Albert, Doerholt Katja, Kitaka Sabrina B, Asiimwe Alice, Judd Ali, Musoke Philippa, Gibb Diana M
Baylor College of Medicine Children's Foundation, Mulago Hospital Paediatric Infectious Diseases Clinic, Kampala, Uganda.
J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):384-92. doi: 10.1097/QAI.0b013e31818cdef5.
Few studies have directly compared response to antiretroviral therapy (ART) between children living in well-resourced and resource-limited settings. In resource-limited settings non-HIV contributors could reduce the beneficial effects of ART. We compare predictors of short-term immunological, virological, and growth response to ART in HIV-infected children in the United Kingdom/Ireland and Kampala.
We analyzed prospective cohort data from 54 UK/Irish hospitals (the Collaborative HIV Paediatric Study) and Mulago Hospital, Kampala, Uganda. Six- and 12-month responses are described among children initiating combination ART (> or = 3 drugs, > or = 2 classes). Six months post-ART, predictors of viral load (VL) suppression <400 copies/mL, CD4% increases > 10%, and height- and weight-for-age z-score increases > or = +0.5 were investigated using logistic regression.
In all, 582 UK/Irish children (76% black African) were younger than 876 Kampala children at ART initiation (median 5.0 vs 7.6 years), with higher CD4% (14%, 8%), lower VL (172,491 and 346,809 copies/mL), and less stunting (-0.8, -2.8) and wasting (-0.6, -2.8). Post-ART, median 12-month changes in the United Kingdom/Ireland and Kampala in CD4% (+12%, +13%) and weight (+0.4, +0.5) were similar, but growth was less in Kampala (+0.20, +0.06, P < 0.001). Younger children in both cohorts had better immunological, weight, and growth responses (all P < 0.001). However, lower pre-ART CD4% predicted better immunological response in the United Kingdom/Ireland but poorer response in Kampala (heterogeneity P = 0.004). Although 70% children in both cohorts had suppressed < 400 copies/mL at 6 months, adolescents starting ART in the United Kingdom/Ireland had somewhat poorer VL responses than those in Kampala (P = 0.15).
Overall immunological and virologic ART responses were similar in children in both cohorts. Poorer CD4 recovery in more immunosuppressed Kampala children and blunted growth responses likely reflect higher background malnutrition and infection rates in Uganda, suggesting the need for earlier HIV diagnosis, nutritional support, cotrimoxazole prophylaxis, and ART.
很少有研究直接比较生活在资源丰富和资源有限环境中的儿童对抗逆转录病毒疗法(ART)的反应。在资源有限的环境中,非艾滋病毒因素可能会降低ART的有益效果。我们比较了英国/爱尔兰和坎帕拉的艾滋病毒感染儿童对ART的短期免疫、病毒学和生长反应的预测因素。
我们分析了来自英国/爱尔兰54家医院(儿童艾滋病毒协作研究)和乌干达坎帕拉穆拉戈医院的前瞻性队列数据。描述了开始联合ART(≥3种药物,≥2类)的儿童在6个月和12个月时的反应。在ART治疗6个月后,使用逻辑回归研究病毒载量(VL)抑制<400拷贝/毫升、CD4%增加>10%以及年龄别身高和体重z评分增加≥+0.5的预测因素。
总共有582名英国/爱尔兰儿童(76%为非洲黑人)在开始ART时比876名坎帕拉儿童年龄小(中位数分别为5.0岁和7.6岁),CD4%更高(分别为14%和8%),VL更低(分别为172491和346809拷贝/毫升),发育迟缓(分别为-0.8和-2.8)和消瘦(分别为-0.6和-2.8)情况更少。ART治疗后,英国/爱尔兰和坎帕拉12个月时CD4%的中位数变化(分别为+12%和+13%)以及体重变化(分别为+0.4和+0.5)相似,但坎帕拉的生长情况较差(分别为+0.20和+0.06,P<0.001)。两个队列中年龄较小的儿童免疫、体重和生长反应更好(均P<0.001)。然而,ART治疗前较低的CD4%在英国/爱尔兰预示着更好的免疫反应,但在坎帕拉则预示着较差的反应(异质性P=0.004)。尽管两个队列中70% 的儿童在6个月时VL抑制<400拷贝/毫升,但在英国/爱尔兰开始ART的青少年VL反应比坎帕拉的青少年略差(P=0.15)。
两个队列中的儿童总体免疫和病毒学ART反应相似。坎帕拉免疫抑制程度更高的儿童CD4恢复较差以及生长反应减弱,可能反映了乌干达更高的背景营养不良和感染率,这表明需要更早地进行艾滋病毒诊断、营养支持、复方新诺明预防和ART治疗。